65,437 trials
Peripheral Vascular Disease
Primary: The Number of Participants With Major Adverse Events (MAE) — 0 participants
Asthma
Primary: Morning Peak Expiratory Flow (mPEF) — 3.3 L/min
Osteoporosis
Primary: Change From Baseline in Urine N-telopeptide of Type 1 Collagen (NTx.) — 49.054; 44.460; 23.676; 34.183 nM BCE/mM Cr
Obstructive Sleep Apnea Syndrome
Primary: Percentage of Oxygen Saturation in the Brain During Sleep — 53.462; 53.13 Percentage of brain oxygen saturation
Cystic Fibrosis
Primary: Number of Participants Reporting Adverse Events (AEs) — 83; 185; 30; 79 participants
Hypertension · Diastolic Dysfunction
Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s
Type 1 Diabetes
Primary: Change in A1c From Baseline to 52 Weeks — -0.8; -0.2 Percent glycated hemoglobin — p=0.05
Melanoma
Primary: Mean Number of Skin Examinations Without Partner Over 4 Months — 0.02; 0.00; 0.02; 0.00 Times examined skin by self
Intubation · Airway Management
Primary: Measure of Intubation Success — 138; 124 Participants
Foramen Ovale, Patent · Heart Catheterization · Heart Septal Defects, Atrial
Primary: Number of Participants With a Successful Implantation. — 62 participants
Healthy
Primary: Cmax of Venlafaxine. — 81.84; 93.50 ng/mL
Healthy
Primary: Cmax of Venlafaxine. — 120.07; 103.59 ng/mL
Parkinson's Disease
Primary: Time to First Occurrence of Dyskinesia — 90.7; 117.1 weeks
Alcohol Abuse · Alcohol Dependence
Primary: Linkage to Alcohol Behavioral Therapy Counseling (i.e., "Aftercare") — 36; 36; 32 participants
Psoriasis Vulgaris
Primary: The Absolute Change in Total Clinical Score (TCS) at End of Treatment Compared to Baseline for Daivobet® Ointment — -5.15 Scores on a scale